APA (7th ed.) Citation

Weinblatt, M. E., Bingham, C. O., Burmester, G., Bykerk, V. P., Furst, D. E., Mariette, X., . . . Emery, P. (2017). A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology, 69(10), 1937. https://doi.org/10.1002/art.40196

Chicago Style (17th ed.) Citation

Weinblatt, Michael E., et al. "A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis." Arthritis & Rheumatology 69, no. 10 (2017): 1937. https://doi.org/10.1002/art.40196.

MLA (9th ed.) Citation

Weinblatt, Michael E., et al. "A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis." Arthritis & Rheumatology, vol. 69, no. 10, 2017, p. 1937, https://doi.org/10.1002/art.40196.